Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 7/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 8/20 | 0.37 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494445 | 0.82 | CYP3A4 (0.55) | BRAFPSIP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17557850 | 0.81 | BRAF (0.43) | BRAFPTGES2PSIP1CYP3A4CYP2C9 | |
| SCHEMBL1873297 | 0.76 | BRAF (0.42) | PTGS1PTGS2BRAF | |
| SCHEMBL22190937 | 0.73 | SMN1; SMN2 (0.44) | PTGS1PTGS2BRAFPTGES2PSIP1 | |
| SCHEMBL3019846 | 0.73 | CYP3A4 (0.49) | PTGS1PTGS2BRAFPSIP1CYP3A4 | |
| SCHEMBL29356384 | 0.73 | SMN1; SMN2 (0.44) | PTGS1PTGS2BRAFPTGES2PSIP1 | |
| SCHEMBL1494607 | 0.73 | PTGS1 (0.38) | PTGS1PTGS2BRAFPSIP1CYP3A4 | |
| SCHEMBL7869189 | 0.72 | CYP2C9 (0.70) | PTGS1PTGS2BRAFPSIP1CYP3A4 | |
| SCHEMBL913405 | 0.70 | BRAF (0.56) | PTGS1PTGS2BRAFCYP3A4CYP2C9 | |
| SCHEMBL18921155 | 0.70 | PSIP1 (0.42) | PTGES2PSIP1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859548-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| EP-2470528-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| US-8563553-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| EP-2470528-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | PTGS1 2925/4885PTGS2 3476/4885BRAF 2/4885 |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | PTGS1 2925/4885PTGS2 3476/4885BRAF 2/4885 |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | PTGS1 2925/4885PTGS2 3476/4885BRAF 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.